{
    "nctId": "NCT00875238",
    "briefTitle": "Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab",
    "officialTitle": "Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cardiac Toxicity, Cardiovascular Complications",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 133,
    "primaryOutcomeMeasure": "Change in cardiac function by echocardiogram",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosed with breast cancer\n\n  * Receiving treatment at Vanderbilt Ingram Cancer Center and other participating oncology practices in middle Tennessee and southern Kentucky\n* Starting a standard doxorubicin hydrochloride regimen for 4 courses\n\n  * Also scheduled to receive trastuzumab (for patients enrolled in sub-study B only)\n* No presence of metastatic disease\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* Karnofsky performance status 60-100%\n* Not pregnant\n* Negative pregnancy test\n* Additional criteria for sub-study A (MRI):\n\n  * Glomerular filtration rate \u2265 60 mL/min\n  * No implanted electronic devices, cochlear implants, metallic implants, shrapnel or neurosurgical clips\n  * No prior adverse reaction to gadolinium-based contrast agents\n  * Must not exceed the weight limit or be too large to fit in the MRI scanner\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior anthracycline chemotherapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}